BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Sells $1,122,500.00 in Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRNGet Rating) CEO Jean Jacques Bienaime sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, January 13th. The stock was sold at an average price of $112.25, for a total transaction of $1,122,500.00. Following the transaction, the chief executive officer now owns 320,424 shares of the company’s stock, valued at approximately $35,967,594. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Tuesday, January 17th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $111.55, for a total transaction of $1,115,500.00.
  • On Tuesday, December 13th, Jean Jacques Bienaime sold 1,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $106.89, for a total transaction of $106,890.00.
  • On Friday, December 2nd, Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $103.98, for a total transaction of $155,970.00.
  • On Monday, October 31st, Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $86.55, for a total transaction of $129,825.00.

BioMarin Pharmaceutical Trading Down 1.3 %

NASDAQ BMRN opened at $109.20 on Friday. The stock has a market capitalization of $20.25 billion, a price-to-earnings ratio of 260.00 and a beta of 0.36. BioMarin Pharmaceutical Inc. has a one year low of $70.73 and a one year high of $114.80. The company has a debt-to-equity ratio of 0.24, a current ratio of 5.15 and a quick ratio of 3.54. The business’s fifty day moving average is $102.31 and its 200-day moving average is $93.27.

BioMarin Pharmaceutical (NASDAQ:BMRNGet Rating) last released its earnings results on Wednesday, October 26th. The biotechnology company reported $0.16 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.04. The company had revenue of $505.30 million for the quarter, compared to analysts’ expectations of $516.03 million. BioMarin Pharmaceutical had a return on equity of 2.50% and a net margin of 4.18%. The business’s revenue for the quarter was up 23.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.03) EPS. Equities research analysts predict that BioMarin Pharmaceutical Inc. will post 0.87 EPS for the current year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of hedge funds have recently made changes to their positions in BMRN. Altshuler Shaham Ltd bought a new stake in BioMarin Pharmaceutical in the 3rd quarter valued at about $25,000. Quadrant Capital Group LLC raised its stake in BioMarin Pharmaceutical by 188.6% in the 2nd quarter. Quadrant Capital Group LLC now owns 355 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 232 shares during the period. Baystate Wealth Management LLC bought a new stake in BioMarin Pharmaceutical in the 4th quarter valued at about $41,000. Acadian Asset Management LLC raised its stake in BioMarin Pharmaceutical by 395.4% in the 1st quarter. Acadian Asset Management LLC now owns 431 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 344 shares during the period. Finally, First Horizon Advisors Inc. raised its stake in BioMarin Pharmaceutical by 1,014.6% in the 2nd quarter. First Horizon Advisors Inc. now owns 535 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 487 shares during the period. 96.26% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Canaccord Genuity Group assumed coverage on shares of BioMarin Pharmaceutical in a research report on Wednesday. They set a “hold” rating and a $119.00 price objective for the company. Oppenheimer raised shares of BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $92.00 to $110.00 in a research report on Monday, October 31st. Royal Bank of Canada raised their price objective on shares of BioMarin Pharmaceutical from $90.00 to $95.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 13th. Wedbush raised their price objective on shares of BioMarin Pharmaceutical from $74.00 to $83.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 11th. Finally, Credit Suisse Group reduced their price target on shares of BioMarin Pharmaceutical from $111.00 to $110.00 and set an “outperform” rating for the company in a research report on Thursday, October 27th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $119.00.

About BioMarin Pharmaceutical

(Get Rating)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

See Also

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.